NCT06110650View on ClinicalTrials.gov

A Study of Surufatinib in the Treatment of Advanced Soft Tissue Sarcoma

NANot yet recruitingINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

November 28, 2023

Primary Completion Date

August 15, 2024

Study Completion Date

August 15, 2025

Conditions
Soft Tissue Sarcoma Adult
Interventions
DRUG

Surufatinib

Surufatinib 300mg orally, once a day, every 21 days for one cycle, treatment until disease progression or intolerance

All Listed Sponsors
lead

Fudan University

OTHER

NCT06110650 - A Study of Surufatinib in the Treatment of Advanced Soft Tissue Sarcoma | Biotech Hunter | Biotech Hunter